DE69833876T2 - Zusammensetzungen und verfahren für die gezielte abgabe von faktoren - Google Patents

Zusammensetzungen und verfahren für die gezielte abgabe von faktoren Download PDF

Info

Publication number
DE69833876T2
DE69833876T2 DE69833876T DE69833876T DE69833876T2 DE 69833876 T2 DE69833876 T2 DE 69833876T2 DE 69833876 T DE69833876 T DE 69833876T DE 69833876 T DE69833876 T DE 69833876T DE 69833876 T2 DE69833876 T2 DE 69833876T2
Authority
DE
Germany
Prior art keywords
cells
specific
cell
binding
factor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69833876T
Other languages
German (de)
English (en)
Other versions
DE69833876D1 (de
Inventor
Lawrence Rockville TAMARKIN
F. Giulio Baltimore PACIOTTI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cytimmune Sciences Inc
Original Assignee
Cytimmune Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/966,940 external-priority patent/US6274552B1/en
Application filed by Cytimmune Sciences Inc filed Critical Cytimmune Sciences Inc
Application granted granted Critical
Publication of DE69833876D1 publication Critical patent/DE69833876D1/de
Publication of DE69833876T2 publication Critical patent/DE69833876T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
DE69833876T 1997-11-10 1998-11-10 Zusammensetzungen und verfahren für die gezielte abgabe von faktoren Expired - Lifetime DE69833876T2 (de)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US966940 1997-11-10
US08/966,940 US6274552B1 (en) 1993-03-18 1997-11-10 Composition and method for delivery of biologically-active factors
US7581198P 1998-02-24 1998-02-24
US75811P 1998-02-24
US8669698P 1998-05-26 1998-05-26
US86696P 1998-05-26
US10745598P 1998-11-06 1998-11-06
US107455P 1998-11-06
PCT/US1998/023931 WO1999024077A2 (en) 1997-11-10 1998-11-10 Compositions and methods for targeted delivery of biologically-active factors

Publications (2)

Publication Number Publication Date
DE69833876D1 DE69833876D1 (de) 2006-05-11
DE69833876T2 true DE69833876T2 (de) 2007-05-24

Family

ID=27491221

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69833876T Expired - Lifetime DE69833876T2 (de) 1997-11-10 1998-11-10 Zusammensetzungen und verfahren für die gezielte abgabe von faktoren

Country Status (9)

Country Link
US (1) US20090035265A1 (cg-RX-API-DMAC7.html)
EP (1) EP1044022B1 (cg-RX-API-DMAC7.html)
JP (1) JP4620243B2 (cg-RX-API-DMAC7.html)
AT (1) ATE320270T1 (cg-RX-API-DMAC7.html)
AU (1) AU760035B2 (cg-RX-API-DMAC7.html)
CA (1) CA2309604C (cg-RX-API-DMAC7.html)
DE (1) DE69833876T2 (cg-RX-API-DMAC7.html)
NZ (1) NZ504291A (cg-RX-API-DMAC7.html)
WO (1) WO1999024077A2 (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010055581A1 (en) 1994-03-18 2001-12-27 Lawrence Tamarkin Composition and method for delivery of biologically-active factors
US6407218B1 (en) 1997-11-10 2002-06-18 Cytimmune Sciences, Inc. Method and compositions for enhancing immune response and for the production of in vitro mabs
JP2009286808A (ja) * 1997-11-10 2009-12-10 Cytimmune Sciences Inc 生物学的に活性な因子の標的化された送達のための組成物および方法
NZ504292A (en) * 1997-11-10 2003-03-28 Cytimmune Sciences Inc Methods and compositions for enhancing immune response using a targeted delivery system and for the production of in vitro mabs
US7229841B2 (en) 2001-04-30 2007-06-12 Cytimmune Sciences, Inc. Colloidal metal compositions and methods
WO2002087509A2 (en) * 2001-04-30 2002-11-07 Cytimmune Sciences, Inc. Colloidal metal compositions and methods
JP2008504216A (ja) * 2003-12-02 2008-02-14 サイトイミューン サイエンシズ インコーポレイテッド モノクローナル抗体の生成のための方法および組成物
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
US8877156B2 (en) 2007-06-26 2014-11-04 New York University Contrast agents anchored by thiols on nanoparticles
JP2011520769A (ja) * 2007-09-21 2011-07-21 サイトイミューン サイエンシズ インコーポレイテッド ナノ治療コロイド金属組成物および方法
WO2009062151A1 (en) 2007-11-08 2009-05-14 Cytimmune Sciences, Inc. Compositions and methods for generating antibodies
AU2009246397B2 (en) 2008-05-13 2013-01-17 University Of Kansas Metal abstraction peptide (MAP) tag and associated methods
WO2013181461A2 (en) 2012-06-01 2013-12-05 University Of Kansas Metal abstraction peptide with superoxide dismutase activity
US10064940B2 (en) 2013-12-11 2018-09-04 Siva Therapeutics Inc. Multifunctional radiation delivery apparatus and method
US20250034221A1 (en) * 2023-07-25 2025-01-30 Zahav Bioscience Llc Cytokine compositions and methods of use thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4963354A (en) * 1987-01-21 1990-10-16 Genentech, Inc. Use of tumor necrosis factor (TNF) as an adjuvant
US5047523A (en) * 1988-08-02 1991-09-10 Ortho Diagnostic Systems Inc. Nucleic acid probe for detection of neisseria gonorrhoea
US5248772A (en) * 1992-01-29 1993-09-28 Coulter Corporation Formation of colloidal metal dispersions using aminodextrans as reductants and protective agents
AU6414994A (en) * 1993-03-18 1994-10-11 Cytimmune Sciences, Inc. Composition and method for reducing toxicity of biologically-active factors
JPH07227299A (ja) * 1994-02-14 1995-08-29 Kyoto Daiichi Kagaku:Kk Dnaの特定塩基配列の検出方法及びその装置
US5521289A (en) * 1994-07-29 1996-05-28 Nanoprobes, Inc. Small organometallic probes
US5686578A (en) * 1994-08-05 1997-11-11 Immunomedics, Inc. Polyspecific immunoconjugates and antibody composites for targeting the multidrug resistant phenotype
JPH11507046A (ja) * 1995-06-07 1999-06-22 イムノメディクス,インコーポレイテッド 診断剤および治療剤の標的部位への改良された送達方法
DE69726674T2 (de) * 1996-04-10 2004-10-21 Sangstat Medical Corp Zellmodulierende konjugate aus elementen aus spezifischen bindungspaaren
DE19622628A1 (de) * 1996-06-05 1997-12-11 Boehringer Mannheim Gmbh Stabilisierung von Metallkonjugaten
JP2000516090A (ja) * 1996-07-26 2000-12-05 スローン―ケッタリング インスティチュート フォー キャンサー リサーチ 遺伝子的免疫化のための方法と試薬
ATE302217T1 (de) * 1997-05-02 2005-09-15 Us Gov Health & Human Serv Immuntoxine, die ein onc protein enthalten, gegen bösartige zellen
DE19726186A1 (de) * 1997-06-20 1998-12-24 Boehringer Ingelheim Int Komplexe für den Transport von Nukleinsäure in höhere eukaryotische Zellen
JP4833862B2 (ja) * 2004-01-28 2011-12-07 サイトイミューン サイエンシズ インコーポレイテッド 官能化コロイド金属組成物および方法
US20060185027A1 (en) * 2004-12-23 2006-08-17 David Bartel Systems and methods for identifying miRNA targets and for altering miRNA and target expression

Also Published As

Publication number Publication date
JP4620243B2 (ja) 2011-01-26
US20090035265A1 (en) 2009-02-05
CA2309604C (en) 2010-01-12
ATE320270T1 (de) 2006-04-15
AU760035B2 (en) 2003-05-08
WO1999024077A3 (en) 1999-10-07
CA2309604A1 (en) 1999-05-20
NZ504291A (en) 2002-10-25
EP1044022A2 (en) 2000-10-18
EP1044022B1 (en) 2006-03-15
AU1394099A (en) 1999-05-31
DE69833876D1 (de) 2006-05-11
JP2001522818A (ja) 2001-11-20
WO1999024077A2 (en) 1999-05-20

Similar Documents

Publication Publication Date Title
US6274552B1 (en) Composition and method for delivery of biologically-active factors
DE69433870T2 (de) Zusammensetzung und methode zur reduktion der toxizität von biologisch-aktiven faktoren
US20090035265A1 (en) Compositions and Methods for Targeted Delivery of Factors
US8785202B2 (en) Colloidal metal compositions and methods
US7790167B2 (en) Methods and compositions for enhancing immune response and for the production of in vitro Mabs
AU2008302035A1 (en) Nanotherapeutic colloidal metal compositions and methods
JP2009215319A (ja) コロイド状金属組成物および方法
US8137989B2 (en) Method for delivering a cytokine using a colloidal metal
AU2005209318A1 (en) Functionalized colloidal metal compositions and methods
DE69833455T2 (de) Verfahren und zusammensetzungen zur verstärkung der immunantwort und zur in-vitro herstellung von monoklonalen antikörpern (mabs)
AU2002259107A1 (en) Colloidal metal compositions and methods
AU2003231660B2 (en) Compositions and methods for targeted delivery of factors
US20250235557A1 (en) Method of gene targeting utilizing outer membrane vesicle
JP2009286808A (ja) 生物学的に活性な因子の標的化された送達のための組成物および方法

Legal Events

Date Code Title Description
8364 No opposition during term of opposition